Home
overview
The means by which a drug is introduced into the body is almost as important as the drug itself. Controlled release systems describe the rate at which the drug is made available to the body once it has been delivered. Using traditional delivery systems the drug is released immediately in a large peak and then drug levels decline rapidly. Drugs incorporating a controlled release system maintain drug concentration within the therapeutic range and thus eliminate the need for frequent dosages.

Controlled release will address the developments and advances occurring in this important field. The conference will address both established and new technologies involved in controlled release drug delivery systems, company development profiles and applications of controlled release strategies. Commercial issues such as regulatory, intellectual property and licensing issues will also be discussed. The meeting aims to bring together leaders in the fields of all aspects of controlled release to analyse the way forward in this important area in drug development.

A unique opportunity to learn from leading industry experts including:
· Dr Ross MacRae, Manager, Formulation Design, Pfizer
· Dr Kalidas Kale, Senior Research Investigator, Bristol-Myers Squibb
· Dr Paul Gellert, Principal Scientist, AstraZeneca
· Dr Alessandro Martini, Director, New Drug Delivery Systems, Pharmacia
· Dr Michael Ausborn, Group Head, Parenteral & Topical Dosage, Novartis
· Dr Berthold Buchholz, Head, Operations & Productions, Boehringer Ingelheim
· Dr Tzuchi Ju, Principal Group Leader, Abbott Laboratories
· Dr Francis Martin, Principal Scientist, ALZA
· Dr Eugene Cooper, Executive Vice President & Chief Technical Officer, Elan Drug Delivery
· Dr Pierandrea Esposito, Director, Drug Delivery, Serono

Key benefits of attending
DISCOVER new indications for existing drugs
IDENTIFY the improvements in oral drug delivery
FIND OUT about the opportunities in DNA delivery
LEARN about polymer-based delivery systems
NETWORK with key experts from major pharmaceutical companies
UNDERSTAND the opportunities, limitations and challenges in controlled release

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr David Brayden

Dr David Brayden, Lecturer, Pharmacology, University College Dublin

9:10 KEYNOTE ADDRESS

Dr Paul Gellert

Dr Paul Gellert, Principal Scientist, AstraZeneca

  • The potential to add value through controlled release drug delivery
  • Approaches for obtaining different release profiles to improve drug performance
  • Identifying the optimum controlled release delivery system
  • The importance of developing a patent strategy for your product
  • The need for improved technologies in the future
  • 9:40 IN-SITU FORMING DRUG DELIVERY SYSTEMS

    Dr Richard Dunn

    Dr Richard Dunn, Principal Research Scientist, Atrix Laboratories

  • Types of in-situ forming delivery systems
  • Advantages of in-situ delivery systems
  • Limitations of in-situ drug delivery
  • Safety and toxicology issues
  • Parameters affecting drug release
  • Applications in local and parenteral drug delivery

    Commercial products using in-situ delivery systems

    Future developments

  • 10:20 ORAL DELIVERY OF PROTEIN AND PEPTIDE THERAPEUTIC MOLECULES

    Dr Steven Dinh

    Dr Steven Dinh, Vice President, Research & Technology, Emisphere Technologies

  • Challenges of oral delivery of macromolecular drugs
  • Novel oral drug delivery technology
  • Mechanism
  • Preclinical evaluation
  • Clinical results
  • 11:00 Morning Coffee

    11:20 PARENTERAL SUSTAINED RELEASE PRODUCTS

    Dr Alessandro Martini

    Dr Alessandro Martini, Director, New Drug Delivery Systems, Pharmacia

  • Rationale for sustained release injectable products
  • Design controlled release parenteral forms
  • Select the right technology (contrast and compare)
  • Polymeric drug delivery systems and beyond
  • Unmet needs and future challenges
  • 12:00 PARENTERAL DEPOT FORMULATIONS

    Dr Michael Ausborn

    Dr Michael Ausborn, Group Head, Parenteral & Topical Dosage Forms, Novartis

  • Needs and gaps – marketing and technical reality
  • Biodegradable and non-biodegradable technologies
  • Microspheres for classical drug substances, peptide and protein delivery
  • Microsphere issues
  • What’s next?
  • 12:40 Lunch

    13:40 ORAL BIOAVAILABILITY ENHANCEMENT

    Dr Hing Kin Chan

    Dr Hing Kin Chan, Business Development Director, Eurand

  • Challenges of oral bioavailability enhancement
  • Limitations of enhancing oral bioavailability
  • Predictive bioavailability enhancement
  • Selection of preliminary formula component to enhance oral delivery
  • Oral bioavailability to control the drug release
  • 14:20 IMPROVEMENT IN THE BIOAVAILABILITY OF WATER INSOLUBLE COMPOUND

    Dr Kalidas Kale

    Dr Kalidas Kale, Senior Research Investigator, Bristol-Myers Squibb

  • Enhancement in the bioavailability of water insoluble compounds
  • Self-Emulsifying Drug Delivery Systems (SEDDS)
  • Water insoluble active compounds
  • Moisture sensitive active compounds
  • Design of SEDDS
  • Characterisation of SEDDS
  • 15:00 THE INFLUENCE OF THE BIOLOGICAL SYSTEM ON ORAL CONTROLLED RELEASE PERFORMANCE IN VIVO

    Dr Hiep Huatan

    Dr Hiep Huatan, Senior Principal Scientist, Pharmaceutical Research & Development, Pfizer, Pfizer

  • The ‘hazardous’ environment of the gut
  • Methods to assess susceptibility in vivo and in vitro
  • Review of susceptibility of technologies to gut environment and food
  • Case study ‘A matrix tablet evaluation by pharmacoscintigraphic methods’
  • Technology selection for maximum probability of success
  • 15:40 Afternoon Tea

    16:00 DELIVERY OF PROTEINS AND PEPTIDES

    Dr Pierandrea Esposito

    Dr Pierandrea Esposito, Director, Drug Delivery, Serono

  • Identification of key molecular properties for successful development of controlled release products
  • Physical or chemical modifications of proteins and peptides
  • Controlled release from injectable systems: present and future challenges
  • Potential and challenges of non-parenteral delivery
  • Oral delivery of proteins and peptides – present and future
  • 16:40 NANOTECHNOLOGY

    Dr Eugene Cooper

    Dr Eugene Cooper, Executive Vice President & Chief Technical Officer, Elan Drug Delivery

  • Need for nanotechnology in the pharmaceutical industry
  • Advantages of drugs developed through nanotechnology
  • Status of current nanotechnology in the pharmaceutical industry
  • Future possibilities with nanotechnology
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Michael Ausborn

    Dr Michael Ausborn, Group Head, Parenteral & Topical Dosage Forms, Novartis

    9:10 MEETING THE DELIVERY CHALLENGES OF THE PROTEOMIC ERA

    Dr Peter Laing

    Dr Peter Laing, Development Director, Lipoxen Technologies

  • Meeting the challenge of genomic/proteomic era – ‘delivery’
  • Opportunities created by drug delivery for protein and peptide based companies
  • Challenges and some solutions for protein and peptide drug delivery problems
  • Improving performance of protein and peptide therapeutics by polymer derivatisation – new developments
  • Latest innovations in protein and peptide delivery
  • Delivery of peptides and proteins via non-parenteral routes
  • 9:40 DNA DELIVERY

    Pia Delaère

    Pia Delaère, Head of B&S Department, Gencell

  • Definitions of gene therapy and gene transfer
  • Goals and limitations of gene transfer technology
  • DNA delivery systems vs viral vectors
  • Improvements in DNA delivery/formulations
  • Safety and efficacy considerations
  • 10:20 ORAL POLYMERIC DRUG DELIVERY AND RECENT DEVELOPMENT

    Dr Tzuchi Ju

    Dr Tzuchi Ju, Principal Group Leader, Abbott Laboratories

  • Overview of polymer-based delivery systems
  • Limitations and selection of polymers: case studies
  • Emerging technologies
  • Future strategies for polymer drug delivery
  • 11:00 Morning Coffee

    11:20 APPLICATIONS OF SUPERCRITICAL FLUIDS TO DRUG DELIVERY OF BIOPHARMACEUTICALS

    Dr Michel Perrut

    Dr Michel Perrut, Chief Technology Officer, Lavipharm

  • What is a Supercritical Fluid?
  • Applications to drug delivery
  • Advantages for biopharmaceuticals
  • Development, challenges and issues
  • Some pertinent examples
  • 12:00 HYDROPHILIC POLYMERS FOR PROTEIN DELIVERY

    Dr Leo de Leede

    Dr Leo de Leede, Director, Octoplus Technologies

  • Controlled and sustained release protein delivery systems
  • Possibilities and restrictions
  • Limitations of currently available technologies
  • Novel concept of preparation in full aqueous environment
  • In vitro vs in vivo characteristics
  • Physical crosslinking opportunities

    Drug targeting modalities

  • 12:40 Lunch

    14:00 BIODEGRADABLE POLYESTERS FOR DRUG DELIVERY SYSTEMS

    Dr Berthold Buchholz

    Dr Berthold Buchholz, Head, Operations & Production, Boehringer Ingelheim

  • Types of biodegradable polyesters
  • Chemical structure and properties
  • Degradation mechanism
  • Applications in parenteral drug delivery systems
  • 14:40 POLYMERIC DELIVERY SOLUTIONS FOR PROTEINS AND INSOLUBLE DRUGS

    Dr Kirk Fowers

    Dr Kirk Fowers, Director, Clinical Development, MacroMed

  • Introduction to biocompartible/biodegradable triblock copolymers
  • Safety, toxicity, and manufacturing considerations of polymer systems
  • Controlled release of proteins and peptides
  • Solubilization of water insoluble compounds
  • Advantages of simple polymer systems
  • 15:20 Afternoon Tea

    15:40 LIPOSOME DRUG DELIVERY SYSTEMS

    Dr Francis Martin

    Dr Francis Martin, Principal Scientist, ALZA

  • Types of liposomes – influence of formulation on pharmacology
  • Recent advances in liposomal technology leading to efficiencies and target-specific drug release
  • Optimisation of liposome-based drug therapy in cancer
  • Review clinical evidence for in vivo tumour targeting
  • Improvements in efficacy and decrease toxicity of therapeutic agents
  • Future developments in liposome technology
  • 16:20 ADVANCED INJECTION DEVICES FOR DELIVERY OF CONTROLLED RELEASE FORMULATIONS

    Kevin Maynard

    Kevin Maynard, Business Development Manager, Imprint Pharmaceuticals

    17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.